Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - A review of the experimental evidence

Atherosclerosis

Volumn 227, Issue 1, 2013, Pages 9-17

  Björkbacka, Harry ^a   Fredrikson, Gunilla Nordin ^a   Nilsson, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmunity; Biomarkers; Immune modulation; Inflammation; Monocytes; Regulatory T cells

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 1BETA; OXIDIZED LOW DENSITY LIPOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; THROMBOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS; ATHEROSCLEROSIS; AUTOIMMUNITY; B-LYMPHOCYTES; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MICE; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84873475820     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.074     Document Type: Review

References (104)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352(16):1685-1695.
3. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6(7):508-519.
4. Hansson G.K., Robertson A.-K.L., Nauclér C.S. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006, 1:297-329.
5. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12(3):204-212.
6. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet 1996, 348(9034):1079-1082.
7. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
8. Maxwell S.R., Webb D.J. COX-2 selective inhibitors - important lessons learned. Lancet 2005, 365(9458):449-451.
9. McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011, 8(9):e1001098.
10. Nilsson J., Hansson G.K. Autoimmunity in atherosclerosis: a protective response losing control?. J Intern Med 2008, 263(5):464-478.
11. Combadiere C., Potteaux S., Rodero M., et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008, 117(13):1649-1657.
12. Saederup N., Chan L., Lira S.A., Charo I.F. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008, 117(13):1642-1648.
13. Stoneman V., Braganza D., Figg N., et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res 2007, 100(6):884-893.
14. Jongstra-Bilen J., Haidari M., Zhu S.N., Chen M., Guha D., Cybulsky M.I. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006, 203(9):2073-2083.
15. Zhu S.N., Chen M., Jongstra-Bilen J., Cybulsky M.I. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J Exp Med 2009, 206(10):2141-2149.
16. Drechsler M., Megens R.T., van Zandvoort M., Weber C., Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010, 122(18):1837-1845.
17. Zernecke A., Bot I., Djalali-Talab Y., et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008, 102(2):209-217.
18. Soehnlein O., Zernecke A., Eriksson E.E., et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 2008, 112(4):1461-1471.
19. Lievens D., von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011, 106(5):827-838.
20. Hsue P.Y., Deeks S.G., Hunt P.W. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012, 205(Suppl. 3):S375-S382.
21. Dansky H.M., Charlton S.A., Harper M.M., Smith J.D. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1997, 94(9):4642-4646.
22. Daugherty A., Pure E., Delfel-Butteiger D., et al. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J Clin Invest 1997, 100(6):1575-1580.
23. Zhou X., Nicoletti A., Elhage R., Hansson G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102(24):2919-2922.
24. Binder C.J., Chang M.K., Shaw P.X., et al. Innate and acquired immunity in atherogenesis. Nat Med 2002, 8(11):1218-1226.
25. Buono C., Binder C.J., Stavrakis G., Witztum J.L., Glimcher L.H., Lichtman A.H. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 2005, 102(5):1596-1601.
26. Lahoute C., Herbin O., Mallat Z., Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 2011, 8(6):348-358.
27. King V.L., Szilvassy S.J., Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol 2002, 22(3):456-461.
28. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85(8):e17-e24.
29. Binder C.J., Hartvigsen K., Chang M.K., et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004, 114(3):427-437.
30. van Es T., van Puijvelde G.H., Ramos O.H., et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009, 388(2):261-265.
31. Taleb S., Romain M., Ramkhelawon B., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009, 206(10):2067-2077.
32. Erbel C., Chen L., Bea F., et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol 2009, 183(12):8167-8175.
33. Kolbus D., Ramos O.H., Berg K.E., et al. CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe(-/-) mice. BMC Immunol 2010, 11:58.
34. Olofsson P.S., Soderstrom L.A., Wagsater D., et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008, 117(10):1292-1301.
35. Chyu K.Y., Zhao X., Dimayuga P.C., et al. CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide. PLoS ONE 2012, 7(2):e30780.
36. Kolbus D., Ljungcrantz I., Soderberg I., et al. TAP1-Deficiency does not alter atherosclerosis development in Apoe(-/-) mice. PLoS ONE 2012, 7(3):e33932.
37. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12(2):178-180.
38. Nakai Y., Iwabuchi K., Fujii S., et al. Natural killer T cells accelerate atherogenesis in mice. Blood 2004, 104(7):2051-2059.
39. Tupin E., Nicoletti A., Elhage R., et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004, 199(3):417-422.
40. Gotsman I., Grabie N., Gupta R., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114(19):2047-2055.
41. van Es T., van Puijvelde G.H., Foks A.C., et al. Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. Atherosclerosis 2010, 209(1):74-80.
42. Robertson A.K., Rudling M., Zhou X., Gorelik L., Flavell R.A., Hansson G.K. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003, 112(9):1342-1350.
43. Mallat Z., Gojova A., Brun V., et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003, 108(10):1232-1237.
44. Steffens S., Burger F., Pelli G., et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 2006, 114(18):1977-1984.
45. Klingenberg R., Ketelhuth D.F., Strodthoff D., Gregori S., Hansson G.K. Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe(-)/(-) mice. Immunobiology 2012, 217(5):540-547.
46. van Puijvelde G.H., Hauer A.D., de Vos P., et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006, 114(18):1968-1976.
47. Klingenberg R., Lebens M., Hermansson A., et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30(5):946-952.
48. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92(9):3893-3897.
49. Hermansson A., Ketelhuth D.F., Strodthoff D., et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010, 207(5):1081-1093.
50. Fredrikson G.N., Soderberg I., Lindholm M., et al. Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003, 23(5):879-884.
51. Maron R., Sukhova G., Faria A.M., et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002, 106(13):1708-1715.
52. Wigren M., Kolbus D., Duner P., et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med 2011, 269(5):546-556.
53. Wigren M., Bengtsson D., Duner P., et al. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res 2009, 104(12):e62-e70.
54. van Puijvelde G.H., van Es T., van Wanrooij E.J., et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(12):2677-2683.
55. Herbin O., Ait-Oufella H., Yu W., et al. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012, 32(3):605-612.
56. Hermansson A., Johansson D.K., Ketelhuth D.F., Andersson J., Zhou X., Hansson G.K. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011, 123(10):1083-1091.
57. Ketelhuth D.F., Hansson G.K. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb Haemost 2011, 106(5):779-786.
58. Mor A., Luboshits G., Planer D., Keren G., George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006, 27(21):2530-2537.
59. Han S.F., Liu P., Zhang W., et al. The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol 2007, 124(1):90-97.
60. Cheng X., Yu X., Ding Y.J., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127(1):89-97.
61. Ammirati E., Cianflone D., Banfi M., et al. Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30(9):1832-1841.
62. Wigren M., Bjorkbacka H., Andersson L., et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol 2012.
63. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167(3):1245-1253.
64. Miyara M., Yoshioka Y., Kitoh A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30(6):899-911.
65. Liu W., Putnam A.L., Xu-Yu Z., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203(7):1701-1711.
66. Zhou L., Chong M.M., Littman D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30(5):646-655.
67. Caligiuri G., Nicoletti A., Poirier B., Hansson G.K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002, 109(6):745-753.
68. Major A.S., Fazio S., Linton M.F. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002, 22(11):1892-1898.
69. Ait-Oufella H., Herbin O., Bouaziz J.D., et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010, 207(8):1579-1587.
70. Kyaw T., Tay C., Khan A., et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010, 185(7):4410-4419.
71. Kyaw T., Tay C., Krishnamurthi S., et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 2011, 109(8):830-840.
72. Kyaw T., Tay C., Hosseini H., et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS ONE 2012, 7(1):e29371.
73. Sage A.P., Tsiantoulas D., Baker L., et al. BAFF receptor deficiency reduces the development of atherosclerosis in mice - brief report. Arterioscler Thromb Vasc Biol 2012, 32(7):1573-1576.
74. Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol 2010, 134(1):47-54.
75. Caligiuri G., Khallou-Laschet J., Vandaele M., et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 2007, 50(6):540-546.
76. Nilsson J., Kovanen P.T. Will autoantibodies help to determine severity and progression of atherosclerosis?. Curr Opin Lipidol 2004, 15(5):499-503.
77. Fredrikson G.N., Schiopu A., Berglund G., Alm R., Shah P.K., Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007, 194(2):e188-e192.
78. Sjogren P., Fredrikson G.N., Samnegard A., et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 2008, 29(18):2218-2226.
79. Schiopu A., Bengtsson J., Soderberg I., et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004, 110(14):2047-2052.
80. Schiopu A., Frendeus B., Jansson B., et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007, 50(24):2313-2318.
81. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19(1):71-82.
82. Swirski F.K., Libby P., Aikawa E., et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007, 117(1):195-205.
83. Tacke F., Alvarez D., Kaplan T.J., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007, 117(1):185-194.
84. Tsou C.L., Peters W., Si Y., et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007, 117(4):902-909.
85. Landsman L., Bar-On L., Zernecke A., et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009, 113(4):963-972.
86. Robbins C.S., Chudnovskiy A., Rauch P.J., et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation 2012, 125(2):364-374.
87. Dutta P., Courties G., Wei Y., et al. Myocardial infarction accelerates atherosclerosis. Nature 2012, 487(7407):325-329.
88. Ziegler-Heitbrock L., Ancuta P., Crowe S., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116(16):e74-e80.
89. Berg K.E., Ljungcrantz I., Andersson L., et al. Elevated CD14++CD16- monocytes predict cardiovascular events. Circ Cardiovasc Genet 2012, 5(1):122-131.
90. McDermott D.H., Fong A.M., Yang Q., et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003, 111(8):1241-1250.
91. Apostolakis S., Baritaki S., Kochiadakis G.E., Igoumenidis N.E., Panutsopulos D., Spandidos D.A. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 2007, 119(1):63-71.
92. Norata G.D., Garlaschelli K., Ongari M., Raselli S., Grigore L., Catapano A.L. Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 2006, 37(6):1558-1561.
93. Afzal A.R., Kiechl S., Daryani Y.P., et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke 2008, 39(7):1972-1978.
94. Koenen R.R., Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med 2011, 3(12):713-725.
95. Weber C. Obstacles and options in the quest for drug candidates against vascular disease. Thromb Haemost 2010, 104(1):1-3.
96. Libby P., Ridker P.M., Hansson G.K. Leducq transatlantic network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54(23):2129-2138.
97. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators. Circulation 1999, 100:230-235.
98. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103(7):926-933.
99. Ridker P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009, 7(Suppl. 1):332-339.
100. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162(4):597-605.
101. Schmitz G., Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2010, 208(1):10-18.
102. Goncalves I., Edsfeldt A., Ko N.Y., et al. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol 2012, 32(6):1505-1512.
103. Corson M.A., Jones P.H., Davidson M.H. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008, 101(12A):41F-50F.
104. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17(11):1410-1422.